



Characterization of colistin tissue pharmacokinetics by microdialysis

Peter Matzneller, William Couet, Patrice Gobin, Markus Müller, Markus Zeitlinger

► To cite this version:

Peter Matzneller, William Couet, Patrice Gobin, Markus Müller, Markus Zeitlinger. Characterization of colistin tissue pharmacokinetics by microdialysis. BMC Pharmacology and Toxicology, 2012, 13 (Suppl 1), pp.A74. 10.1186/2050-6511-13-S1-A74 . inserm-00732898

HAL Id: inserm-00732898

<https://inserm.hal.science/inserm-00732898>

Submitted on 17 Sep 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

MEETING ABSTRACT

Open Access

Characterization of colistin tissue pharmacokinetics by microdialysis

Peter Matzneller¹, William Couet², Patrice Gobin², Markus Müller¹, Markus Zeitlinger^{1*}

From 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the Croatian, Serbian and Slovenian Pharmacological Societies.

Graz, Austria. 20-21 September 2012

Background

Colistin is an important antimicrobial treatment option against multidrug-resistant Gram-negative bacteria. However, colistin is a large and chemically complex molecule and information on its ability to penetrate into tissues remains sparse. Thus, the present work investigated the ability of microdialysis (μ D) to assess pharmacokinetics (PK) of colistin in the interstitium of soft tissues, i.e. at a potential site of infection.

Methods

In vitro: Colistin recovery for linear CMA 66 μ D probes with a molecular weight cut-off of 100 kDa was assessed through forward and reverse μ D for different colistin concentrations. *In vivo*: Three male healthy volunteers received a single intravenous dose of 2.5 million international units of the inactive prodrug colistin methanesulfonate. Colistin concentrations in plasma and in μ D samples obtained from two probes inserted into subcutaneous adipose tissue of the thigh were determined. Retrodialysis was used for probe calibration. In both settings, μ D was performed with and without addition of albumin to perfusion solutions and colistin was quantified by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

Results

In vitro, colistin recovery was constant over time and showed mean recovery values of 52 ± 3 and $71 \pm 8\%$ for forward and reverse μ D, respectively. *In vivo*, recovery of colistin was $43 \pm 15\%$. In both settings, colistin recovery was not improved by addition of albumin to μ D perfusion solutions. Due to small volumes, reliable quantification of

colistin was not possible in some μ D samples, yet maximum concentrations in adipose tissue were relatively high ($0.76 \pm 0.21 \mu\text{g/mL}$) compared with those in plasma ($1.2 \pm 0.43 \mu\text{g/mL}$) attesting for extra-vascular distribution.

Conclusions

The present data demonstrate the feasibility of μ D for evaluation of colistin tissue pharmacokinetics and show opportunities for optimization of experimental setting.

Author details

¹Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria. ²Inserm ERI-23, Faculty of Medicine, University of Poitiers, 86022 Poitiers Cedex, France.

Published: 17 September 2012

doi:10.1186/2050-6511-13-S1-A74

Cite this article as: Matzneller et al.: Characterization of colistin tissue pharmacokinetics by microdialysis. *BMC Pharmacology and Toxicology* 2012 **13**(Suppl 1):A74.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: markus.zeitlinger@meduniwien.ac.at

¹Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria

Full list of author information is available at the end of the article